Patheon Closes Acquisition of IRIX Pharmaceuticals

Patheon Closes Acquisition of IRIX Pharmaceuticals

DURHAM, NC--(Marketwired - April 01, 2015) - Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, has closed the previously announced transaction to acquire IRIX Pharmaceuticals, a Florence, S.C.-headquartered company that specializes in making difficult to manufacture Active Pharmaceutical Ingredients (API) for drugs from early and late development, through commercial launch. With the acquisition, Patheon establishes a North American presence for comprehensive API development and manufacturing to address customers' most challenging needs for drugs in all development phases. 

About Patheon

Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.